Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7153629 | 0.96 | VDR (0.61) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7150688 | 0.95 | VDR (0.67) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7151289 | 0.93 | VDR (0.65) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7152679 | 0.90 | VDR (0.63) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7152541 | 0.90 | VDR (0.64) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7155145 | 0.90 | VDR (0.64) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7153633 | 0.88 | VDR (0.67) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7152608 | 0.88 | VDR (0.70) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL8084283 | 0.88 | VDR (0.64) | VDRADORA3SLC6A2NR1I2PGR | |
| SCHEMBL7152194 | 0.88 | VDR (0.64) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531459-B1 | Therapy of or prophylaxis against osteoporosis; generating new bone material; treating disease characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-11 | — | — | US | claimed |
| US-6531459-B1 | Therapy of or prophylaxis against osteoporosis; generating new bone material; treating disease characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-11 | — | — | US | disclosed |